Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • About us
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • Press releases
  • Investors & Media
    • Share information
    • Financial Reports
      • Annual reports
      • Interim reports
      • Year-end reports
    • Presentations
    • Media
      • Image library
      • Video library
    • Analyst Coverage
    • Prospectuses
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • Events
      • Financial calendar
      • General meetings
  • Contact
    • Career
    • Business development
Skip to content
21 March 2023

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
AllAnnual reportInterim ReportNewsNewsletterPress releaseYear end reportRegulatory posts
21 March 2023 Invitation to Scandion Oncology webcast and conference call March 28, 2023 Download Presentation Webcast Workbook
22 February 2023 Scandion Oncology – Q4 & year-end report 2022 Download Presentation Webcast Workbook
15 February 2023 Invitation to Scandion Oncology webcast and conference call February 22, 2023 Download Presentation Webcast Workbook
19 January 2023 Scandion Oncology A/S: Scandion Oncology receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101 Download Presentation Webcast Workbook
18 January 2023 Scandion Oncology A/S: Scandion Oncology appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management Download Presentation Webcast Workbook
5 December 2022 Scandion Oncology announces share purchase by incoming President & CEO Download Presentation Webcast Workbook
1 December 2022 Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer Download Presentation Webcast Workbook
23 November 2022 Scandion Oncology announces share purchase by member of the Board of Directors Download Presentation Webcast Workbook
16 November 2022 Scandion Oncology – Interim Report Q3 2022 Download Presentation Webcast Workbook
10 November 2022 Invitation to Scandion Oncology webcast and conference call November 16, 2022 Download Presentation Webcast Workbook
28 October 2022 Scandion Oncology Announces Results of Extraordinary General Meeting Download Presentation Webcast Workbook
13 October 2022 Scandion Oncology – Notice convening an Extraordinary General Meeting Download Presentation Webcast Workbook
  1. Frontpage

About us

  • About us
  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

Investors & Media

  • Investors & Media
  • Share information
  • Financial Reports
  • Presentations
  • Media
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us


Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.